Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Suntory Pharmaceutical |
---|---|
Information provided by: | Suntory Pharmaceutical |
ClinicalTrials.gov Identifier: | NCT00030121 |
The purpose of this study is to determine whether Carperitide is safe and effective in the management of Acute Respiratory Distress Syndrome (ARDS).
Condition | Intervention | Phase |
---|---|---|
Respiratory Distress Syndrome |
Drug: recombinant human atrial natriuretic polypeptide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Evaluation of the Safety and Efficacy of Carperitide Infusion in Patients With ARDS |
Study Start Date: | December 1999 |
Acute respiratory distress syndrome (ARDS is a severe form of acute lung injury. ARDS is characterized by an increase in pulmonary vascular permeability resulting from a non-cardiogenic cause, leading to an increased vascular water volume, pulmonary inflammation, and severe hypoxemia. Conventional therapy for ARDS is primarily respiratory management by mechanical ventilation using positive end-expiratory pressure (PEEP). Mechanical ventilation is the major management concern in patients with ARDS, due to its higher risk of infections and morbidity. Treatment with Carperitide may reduce time on the ventilator by reducing pulmonary edema and by improving gas exchange. The results of Carperitide studies in animals and humans support the idea that the hormone will be effective in managing the acute pulmonary complications and hypoxemia seen in ARDS.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion:
In order to participate in the study, patients must:
Exclusion:
In order to participate in the study, patients must not meet any of the following criteria:
Study ID Numbers: | SPI-001 |
Study First Received: | January 31, 2002 |
Last Updated: | February 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00030121 |
Health Authority: | United States: Food and Drug Administration |
Acute Respiratory Distress Acute Lung Injury |
Respiratory Tract Diseases Lung Diseases Respiration Disorders Respiratory Distress Syndrome, Adult Acute respiratory distress syndrome |
Pathologic Processes Disease Syndrome |